Pharma major Lupin announced that it has received approval for its Meloxicam Capsules, 5 mg and 10 mg, from the United States Food and Drug Administration (US FDA), to market a generic equivalent of Vivlodex Capsules, 5 mg and 10 mg, of Zyla Life Sciences US.
The product would be manufactured at Lupin’s Aurangabad facility, India, and is expected to be launched shortly. Meloxicam Capsules, 5 mg and 10 mg, are indicated for management of osteoarthritis (OA) pain.
Also read: BDR to make Gilead drug for Cipla
Meloxicam Capsules (RLD: Vivlodex®) had an annual sales of approximately USD 14 million in the U.S. (IQVIA MAT March 2020).
The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.
